The European Medicines Authority supports transparency, medical research, and innovation through the new Clinical Trials Regulation (CTR) which regulates the harmonisation of assessment and supervision of clinical trials throughout Europe via the Clinical Trials Information System (CTIS).
For more information click here.
Medical Product Alert N°2/2026: Falsified JAKAVI (ruxolitinib) Falsified JAKAVI (ruxolitinib) identified in the WHO Eastern Mediterranean and European regions